United States Ex Rel. Bidani v. Lewis

264 F. Supp. 2d 612, 2003 U.S. Dist. LEXIS 3291, 2003 WL 925998
CourtDistrict Court, N.D. Illinois
DecidedMarch 4, 2003
Docket97 C 6502
StatusPublished
Cited by11 cases

This text of 264 F. Supp. 2d 612 (United States Ex Rel. Bidani v. Lewis) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States Ex Rel. Bidani v. Lewis, 264 F. Supp. 2d 612, 2003 U.S. Dist. LEXIS 3291, 2003 WL 925998 (N.D. Ill. 2003).

Opinion

MEMORANDUM OPINION AND ORDER

MORAN, Senior District Judge.

Plaintiff Anil K. Bidani M.D. (Bidani) brings this qui tarn action pursuant to the False Claims Act, 31 U.S.C. 3729. Defendants Edmund J. Lewis (Lewis). American Medical Supply Corporation (AMS), and Circle Medical Management Corporation (CMM) move for summary judgment. *614 For the following reasons, their motion is denied.

BACKGROUND

The facts and procedural history of this case are contained in various prior opinions. Bidani v. Lewis et al., 1998 WL 1820753 (N.D.Ill. Dec. 29, 1998); Bidani v. Lewis et al., 1999 WL 168053 (N.D.Ill. Mar. 12, 1999); Bidani v. Lewis et al., 2001 WL 32868 (N.D.Ill. Jan 12, 2001); Bidani v. Lewis et al., 2001 WL 747524 (N.D.Ill. June 29, 2001); Bidani v. Lewis et al., 2001 WL 1609377 (N.D.Ill. Dec. 14, 2001). Relevant to this motion, defendant AMS, wholly-owned by defendant Lewis, is a corporation engaged in the business of selling medical supplies. AMS paid Abbot Laboratories and Baxter Healthcare Corporation to provide supplies and equipment to dialysis patients and then submitted claims to Medicare for reimbursement. Abbot and Baxter gave AMS discounts and rebates from the list prices it charged for supplies. AMS did not report receiving these discounts in its claims to Medicare.

One count of the complaint remains. Bidani alleges that the supply discounts received by defendants were illegal kickbacks under the Social Security Act, 42 U.S.C. 1320a-7b. He asserts that the alleged violation of the anti-kickback statute was material in the government’s treatment of the Medicare reimbursement claims and as such the submissions violate the False Claims Act, 31 U.S.C. 3729, et. seq.

DISCUSSION

Summary judgment is appropriate only if there are no genuine issues of material fact and the moving party is entitled to judgment as a matter of law. Celotex Corp. v. Catrett, 477 U.S. 317, 322-23, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). We draw all inferences and view all admissible evidence in the light most favorable to the non-moving party. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986).

During the relevant time period, Medicare’s anti-kickback statute (AKS) prohibited receiving remuneration for purchasing supplies that are reimbursable. 42 U.S.C § 1320a-7b(b)(l). Discounts are considered remuneration unless “the reduction in price is properly disclosed and appropriately reflected in the costs claimed or charges made by the provider.” 42 U.S.C. 1320a-7b(b)(3)(A). The False Claims Act (FCA) prohibits knowingly presenting a false or fraudulent claim for payment or approval to the government. 31 U.S.C. § 3729(a)(1).

Bidani’s FCA claim is premised on a theory of implied certification. Under this theory “a claim made in contravention of statutory or regulatory requirements may be deemed ‘false’ under the FCA in cases where the defendant’s certification of compliance with the statutes and regulations in question is a condition of receiving funds from the Government.” Mikes v. Straus, 84 F.Supp.2d 427, 434 (S.D.N.Y.1999), citing Luckey v. Baxter Healthcare Corp., 2 F.Supp.2d 1034, 1045 (N.D.Ill.1998), aff'd 183 F.3d 730, 732 (7th Cir.1999), cert. denied, 528 U.S. 1038, 120 S.Ct. 562, 145 L.Ed.2d 439. To succeed, Bidani must show that the alleged AKS violation was material to the government’s treatment of defendants’ Medicare claims. Luckey., 183 F.3d at 732. Defendants move for summary judgment on the grounds that Bidani has failed to offer evidence to satisfy this materiality requirement. 1

*615 Courts have split over whether the FCA materiality element requires a showing of outcome materiality (that a falsehood or misrepresentation affects the government’s ultimate decision to remit fund) or claim materiality (that the misrepresentation is material to a defendant’s claim of right). See generally U.S. v. Southland Management Corp., 288 F.3d 665, 675-6 (5th Cir.2002). In addressing this issue the Seventh Circuit leans toward an outcome materiality definition, stating that an omission must be “material to the government’s buying decision.” Luckey, 183 F.3d at 732. The courts in this district have followed suit. Sharp v. Consolidated Medical Transport, Inc., 2001 WL 1035720, *8 (N.D.Ill.2001) (must show that the goal was to convince the government to pay claims it would not otherwise have paid); King v. F.E. Moran, Inc., 2002 WL 2003219 *10 (N.D.Ill.2002) (the issue is whether the government would have paid or even allowed defendant to keep its contract if it had known of the alleged fraud).

But even knowing that the more stringent outcome materiality test applies, we are still left with the task of flushing out what evidence would suffice to satisfy the element. Since there was no disclosure, how the government would have treated defendants’ individual claims is a hypothetical question. So we turn instead to the inquiries of whether compliance with the AKS was so important to the Medicare reimbursement process or so central to Medicare reimbursement agreements that compliance with the AKS was a condition of reimbursement so that failure to disclose non-compliance resulted in wrongful payments.

In support of their motion, defendants submit commentary for 1992 amendments to the Medicare program setting caps for reimbursement for the supplies at issue in this case. See 42 CFR, part 414 (effective 12/17/1992). The commentary discusses findings by the Office of Inspector General for the Department of Health & Human Services (OIG) and the Health Care Financing Administration (HCFA), which recognize that the government does not have access to suppliers costs and that real costs are often lower than the set caps. Defendants assert that these comments show that failure to disclose the discounts was not material since the government payment amount would have been the same regardless of the actual cost of the supplies. 2 But defendants misread the allegations against them.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States ex rel. Kroening v. Forest Pharmaceuticals, Inc.
155 F. Supp. 3d 882 (E.D. Wisconsin, 2016)
United States Ex Rel. Westmoreland v. Amgen, Inc.
812 F. Supp. 2d 39 (D. Massachusetts, 2011)
United States Ex Rel. Lisitza v. Johnson & Johnson
765 F. Supp. 2d 112 (D. Massachusetts, 2011)
Mason v. Medline Industries, Inc.
731 F. Supp. 2d 730 (N.D. Illinois, 2010)
US Ex Rel. Kennedy v. AVENTIS PHARMACEUTICALS, INC.
610 F. Supp. 2d 938 (N.D. Illinois, 2009)
United States Ex Rel. Pogue v. Diabetes Treatment Centers of America
565 F. Supp. 2d 153 (District of Columbia, 2008)
United States v. Rogan
459 F. Supp. 2d 692 (N.D. Illinois, 2006)
US Ex Rel. Holder v. Special Devices, Inc.
296 F. Supp. 2d 1167 (C.D. California, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
264 F. Supp. 2d 612, 2003 U.S. Dist. LEXIS 3291, 2003 WL 925998, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-bidani-v-lewis-ilnd-2003.